Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Plus PD-1 Inhibitor and IP Bevacizumab in Gastric Cancer With Peritoneal Metastasis
NCT06487715Phase 2Enrolling by invitation
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in gastric cancer (GC). Primary endpoint: Overall Survival Rate at 1 year. Started Mar 2024; status: enrolling by invitation.
02
Drugs
bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06487715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487715.